![Duane Dorn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Duane Dorn
Finanzdirektor/CFO bei CDx Diagnostics, Inc.
Profil
Duane Dorn is currently the Chief Operating & Financial Officer at CDx Diagnostics, Inc. He holds an MBA from St. Bonaventure University.
Aktive Positionen von Duane Dorn
Unternehmen | Position | Beginn |
---|---|---|
CDx Diagnostics, Inc.
![]() CDx Diagnostics, Inc. Medical SpecialtiesHealth Technology CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY. | Finanzdirektor/CFO | - |
Ausbildung von Duane Dorn
St. Bonaventure University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
CDx Diagnostics, Inc.
![]() CDx Diagnostics, Inc. Medical SpecialtiesHealth Technology CDx Diagnostics, Inc. develops and delivers instruments for detection and prevention of cancers. It is a specialized pathology lab that utilizes patented CDx Technology to analyze a disaggregated tissue specimen of the entire thickness of the suspect epithelium. The firm involves in detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with unique tools to enhance their detection of precancerous change through complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis. The company was founded by Mark Rutenberg and Drore Eisen in 1997 and is headquarters in Suffern, NY. | Health Technology |